TNFSF13B and systemic lupus erythematosus: Belimumab is a human IgG1 anti-BAFF mAb that, in 2011, became the first biologic drug approved by the United States Food and Drug Administration (FDA) for use in SLE patients with active, autoantibody-positive disease already on standard therapy (Dubey et al., 2011).